COVID-19: Amgen is committed to keeping our patients, customers, staff, and their families safe. Click here for more information.
RIABNI™ (rituximab-arrx) is indicated for the treatment of adult patients with:
RIABNI™ (rituximab-arrx) is indicated for the treatment of adult...Read more patients with:
New Indication
For patients with moderate to severe RHEUMATOID ARTHRITIS (RA)
For questions regarding access or reimbursement support, please contact Amgen Assist® at 866-264-2778.
For questions regarding access or reimbursement support, please contact Amgen Assist® at 866-264-2778.
RIABNITM IS FDA APPROVED FOR ALL AVAILABLE RITUXAN® INDICATIONS1,2,*
FDA = Food and Drug Administration.
*RIABNI™ is also indicated for the treatment of Granulomatosis with Polyangiitis (GPA) (Wegener’s granulomatosis) and Microscopic Polyangiitis (MPA) in adult patients.
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Amgen at 1-800-772-6436.
Please see the full Prescribing Information, including BOXED WARNINGS and Medication Guide, for additional Important Safety Information.RIABNI™ (rituximab-arrx) is indicated for the treatment of adult patients with:
RIABNI™, in combination with fludarabine and cyclophosphamide (FC), is indicated for the treatment of adult patients with previously untreated and previously treated CD20-positive CLL.
RIABNI™, in combination with methotrexate, is indicated for the treatment of adult patients with moderately- to severely- active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.
RIABNI™, in combination with glucocorticoids, is indicated for the treatment of adult patients with Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA).
Rituxan® is a registered trademark of Biogen.
RIABNI™ is a trademark of Amgen, Inc.
Important Safety Information
BOXED WARNINGS: FATAL INFUSION-RELATED REACTIONS, SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION, PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY
Rituxan® is a registered trademark of Biogen.
RIABNI™ is a trademark of Amgen, Inc.
References: 1. RIABNI™ (rituximab-arrx) Prescribing Information, Amgen Inc. 2. RITUXAN® (rituximab) full Prescribing Information, Genentech, Inc.